You are here
Nicole van GriekenDr van Grieken, a pathologist, presents the past, present and future status of molecular biology in tumour research. She reviews the history of technological development that has led to molecular markers, comments on how comprehensive molecular analyses is improving our understanding of tumour biology and clinical behaviour, and addresses the challenges that remain in making molecular markers useful predictive tools. She also reviews the exciting potential value of liquid biopsies for diagnosis and follow up in cancer patients.
Eric Van CutsemNew ESMO clinical practice guidelines on metastatic colorectal cancer were published in 2016. Dr Van Cutsem builds real-life scenarios around these guidelines using case studies and interactive questions where he asks the audience to select a treatment option for each case study. Based on the answers, he then engages the panel to contribute their expertise to explain why they would select a particular option over another in their practices.
Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, et al.J Clin Oncol. 2016 Sep 6. [Epub ahead of print]
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, et al.Lancet Oncol 2016;17:1426-1434.
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, et al.Lancet Oncol 2016;17:1543-1557.